Beijing Tong Ren Tang Chinese Medicine Renews PRC Distribution Deal With Controlling Shareholder

Beijing Tong Ren Tang Chinese Medicine Co ( (HK:3613) ) has issued an update.

Beijing Tong Ren Tang Chinese Medicine has agreed to renew its PRC distribution framework agreement with its controlling shareholder, Tong Ren Tang Holdings, for a further three-year term from 1 January 2026 to 31 December 2028, ensuring continuity of its mainland China distribution arrangements. Under the renewed non-exclusive framework, the Tong Ren Tang Group may continue to purchase products from the listed company for distribution or production use in China, with pricing set by reference to prevailing market levels and benchmarked regularly against transactions with at least two independent third parties to ensure terms are no more favorable than those offered to outsiders; because the deal constitutes a continuing connected transaction with annual caps exceeding key thresholds, it will require independent shareholders’ approval, an independent financial adviser’s opinion and standard disclosure and review processes, underscoring governance scrutiny around related-party dealings.

The most recent analyst rating on (HK:3613) stock is a Hold with a HK$9.50 price target. To see the full list of analyst forecasts on Beijing Tong Ren Tang Chinese Medicine Co stock, see the HK:3613 Stock Forecast page.

More about Beijing Tong Ren Tang Chinese Medicine Co

Beijing Tong Ren Tang Chinese Medicine Company Limited is a Hong Kong–incorporated company engaged in the distribution and sale of traditional Chinese medicine products, leveraging the Tong Ren Tang brand and network, with a key market focus on the Chinese mainland through related-party distributors within the broader Tong Ren Tang Group.

Average Trading Volume: 1,007,751

Technical Sentiment Signal: Sell

Current Market Cap: HK$7.26B

See more data about 3613 stock on TipRanks’ Stock Analysis page.